In this video from the Bleeding Disorders Community, hemophilia patients and their families talk about how the disease has affected their lives but more importantly, how they haven’t let the disease redefine who they are as people. MORE: Three tips for coping with a hemophilia…
Search results for:
Creating personalized hemophilia B care is an important part of hemophilia B management.Your healthcare team can set up a treatment plan based on your specific needs and the severity of your symptoms.
An enzyme called activate protein C (APC), which prevents the formation of blood clots and therefore promotes bleeding could be targeted to treat hemophilia, suggests a study conducted by researcher at the University of Cambridge and the Children’s Hospital of Philadelphia.
Receiving a hemophilia diagnosis can leave patients and their caregivers with many unanswered questions about the disease. Many want to know how to find information, connect with other patients and families, and get support. Here are answers to some frequently asked questions about hemophilia: What is hemophilia?…
Approximately 30,000 males have hemophilia in the U.S., according to estimates from a recent study, which also found that patients with hemophilia are generally young and that the disease is more common in Northeastern and Midwestern states. The study, “Occurrence rates of haemophilia among males in…
https://www.youtube.com/watch?v=pTIVORH7anc This video from Wochit News is all about a new treatment for severe hemophilia A. The Children’s Hospital of Los Angeles, California, has developed a breakthrough treatment that can reduce the bleeding episodes in people living with hemophilia A by up to 90 percent. MORE: Emicizumab shows…
When parenting a child with hemophilia, it’s important to understand how you can support them as they learn to live with the bleeding disorder. The two most common types of hemophilia, type A and type B, primarily affect males, while hemophilia C affects both…
The once-weekly injection therapy marstacimab is being considered for approval in both the U.S. and Europe for people with hemophilia A and hemophilia B who don’t have inhibitors. The U.S. Food and Drug Administration (FDA) is expected to decide on it in late 2024, while a decision from the European…
Hemophilia B is a rare genetic bleeding disorder that impairs the blood’s ability to clot properly.